Table 3 Published meta-analysis or systemic reviews about RTX vs. CYC in the treatment of IMN
Author | Year | Meta-analysis type | Number of arms | Number of studies | Treatment group | Control group | Risk ratio of overall remission | Risk ratio of complete remission | Conditions |
|---|---|---|---|---|---|---|---|---|---|
Lu [25] | 2020 | Direct meta-analysis | 2 | 8 | RTX | Other treatments including CYC | 1.6, 95% CI 0.48–5.54 | NA |  |
Zhang [24] | 2018 | Direct meta-analysis | 2 | 5 | RTX | Other treatments including CYC | NA | 1.6. 95% CI 0.96–2.66 |  |
Ou [23] | 2021 | Direct meta-analysis | 2 | 11 | RTX | Other treatments including CYC | 3.06. 95% CI 1.35–6.94 | 2.6. 95% CI 0.86–7.89 |  |
Zheng [29] | 2019 | Network meta-analysis | 13 | 48 | CYC | RTX | 1.03. 95% CI 0.6–1.7 | NA |  |
Chen [30] | 2022 | Network meta-analysis | 10 | 25 | RTX | CYC | 1.32. 95% CI 0.15–11.61 | NA | Proteinuria < 8 g/d |
|  |  |  |  |  | CYC | RTX | 1.42. 95% CI 0.21–9.65 | NA | Proteinuria > 8 g/d |
|  |  |  |  |  | CYC | RTX + TAC | 1.00. 95% CI 0.15–6.55 | NA | Proteinuria > 8 g/d |
Bose [31] | 2022 | Network meta-analysis | 13 | 56 | CYC | RTX | NA | 0.35. 95% CI 0.10–1.24 |  |
Dai [27] | 2020 | Network meta-analysis | 9 | 75 | RTX | CYC | 1.51. 95% CI 0.7–3.21 | NA |  |
Chen [28] | 2022 | Network meta-analysis | 9 | 24 | RTX < 2 g | CYC | 0.35. 95% CI 0.08–1.62 | NA | At 12 months |
|  |  |  |  |  | RTX > 2 g | CYC | 0.5. 95% CI 0.16–1.57 | NA | At 12 months |
Liu [26] | 2022 | Network meta-analysis | 12 | 51 | RTX | CYC | 1. 95% CI 0.72–1.39 | NA |  |